Posts

AstraZeneca’s Camizestrant Misses Key First-Line Breast-Cancer Trial Goal

on

FDA approves AstraZeneca’s oral SERD camizestrant despite negative advisory-panel vote

on

Will EU prescribers be swayed by AstraZeneca’s Etcamah case?

on

AstraZeneca’s pipeline struggles continue with disappointing late-stage cancer and rare disease data

on

AZ wins EU nod for camizestrant

on

ASCO26: AstraZeneca unveils data it hopes will persuade FDA to approve oral SERD

on

FDA delays camizestrant breast cancer drug decision after ODAC vote against benefit-risk profile

on

AstraZeneca Wins EU Backing for Breast Cancer Drug, Splitting With FDA Panel

on

Biopharma Bites: AstraZeneca's Camizestrant Faces FDA ODAC Scrutiny Amid Trial Design Concerns

on

FDA's Oncologic Drugs Advisory Committee to Review AstraZeneca's Cancer Drugs in First Meeting in 9 Months

on

AstraZeneca Details Its Oral SERD 'Switching' Regimen Amid Feasibility Questions

on